First Patient dosed in Ph 1 Trial of IDE034
“This is an important milestone for IDE034 as well as our broader ADC/DDR portfolio focused on exploring combinations of highly selective TOP1 ADCs with agents targeting the DDR pathway. We are excited to begin dosing patients with IDE034, a B7H3/PTK7 bispecific ADC that has demonstrated promising signs of efficacy as a monotherapy and synergy in combination with IDE161 across several preclinical tumor cell models. IDE034 is our second proprietary TOP1 ADC, building on the progress we have made with IDE849, our DLL3 TOP1 ADC currently in Phase 1 for SCLC and NEC, and represents another potentially first-in-class therapy for cancer patients in need of new and improved treatment options,” said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a